跳至主要内容
临床试验/NCT00396916
NCT00396916已完成不适用

The Value of Novel Imaging Modality, Hybrid PET/CT, Using F18-Flurodeoxyglucose(FDG) in the Assessment of Cancer Patients. Impact of PET/CT on Clinical Management of Patients With Rising Tumor Markers and no Other Evidence of Disease and in Patients With Metastatic Cancer of Unknown Origin

Rambam Health Care Campus1 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2004年12月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
45
试验地点
1
主要终点
the impact of the imaging modality on patient management

研究概览

简要总结

The purpose of the present study is to assess the role of hybrid PET/CT imaging diagnosis of active malignancy in cancer patients with rising tumor markers after treatment and in the diagnosis of primary tumor in patients with metastatic cancer of unknown origin. The clinical impact of PET/CT in the management and treatment of these two groups of cancer patients will be evaluated

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Cancer patients in complete remission after treatment, with serial elevation of serum tumor markers and negative CT or other conventional imaging test.
  • Patients with newly diagnosed metastatic cancer with unknown primary tumor
  • Glucose levels below 150-200
  • Patient signed informed consent

排除标准

  • Pregnant or lactating women
  • Patient unable or not willing to tolerate the test until its completion
  • One or more of the inclusion criteria is not fulfilled

结局指标

主要结局

the impact of the imaging modality on patient management

次要结局

  • the impact of the imaging modality on patient management

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验